The estimated Net Worth of David J Moss is at least $8.68 Milion dollars as of 17 March 2023. Mr Moss owns over 2,500 units of INmune Bio stock worth over $7,788,441 and over the last 5 years he sold INMB stock worth over $586,680. In addition, he makes $300,000 as CFO a Treasurer & Sec. at INmune Bio.
Mr has made over 9 trades of the INmune Bio stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 2,500 units of INMB stock worth $16,075 on 17 March 2023.
The largest trade he's ever made was exercising 25,000 units of INmune Bio stock on 16 July 2021 worth over $97,750. On average, Mr trades about 5,029 units every 86 days since 2019. As of 17 March 2023 he still owns at least 1,250,151 units of INmune Bio stock.
You can see the complete history of Mr Moss stock trades at the bottom of the page.
David J. Moss M.B.A. is the CFO, Treasurer & Sec. at INmune Bio.
As the CFO a Treasurer & Sec. of INmune Bio, the total compensation of Mr A at INmune Bio is $300,000. There are 1 executives at INmune Bio getting paid more, with Dr. Raymond Joseph Tesi M.D. having the highest compensation of $455,000.
Mr A is 51, he's been the CFO a Treasurer & Sec. of INmune Bio since . There are 4 older and no younger executives at INmune Bio. The oldest executive at INmune Bio, Inc. is Dr. Raymond Joseph Tesi, 65, who is the Co-Founder, Pres, CEO, Chief Medical Officer & Chairman.
David's mailing address filed with the SEC is C/O INMUNE BIO INC., 225 NE MIZNER BLVD., SUITE 640, BOCA RATON,, FL, 33432.
Over the last 5 years, insiders at INmune Bio have traded over $5,236,202 worth of INmune Bio stock and bought 82,618 units worth $534,813 . The most active insiders traders include Linda F Powers, Edgardo Jr Baracchini a Inc Xencor. On average, INmune Bio executives and independent directors trade stock every 51 days with the average trade being worth of $117,087. The most recent stock trade was executed by Scott Juda on 25 June 2024, trading 5,000 units of INMB stock currently worth $36,350.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
INmune Bio executives and other stock owners filed with the SEC include: